anti-CD19 CAR-T cells

Anti-CD19 CAR-T cells represent a class of adoptive cell therapy where T lymphocytes are genetically engineered to express a chimeric antigen receptor (CAR) specifically designed to recognize and bind to the CD19 protein. CD19 is a cell surface antigen found on B-lineage cells, including malignant B cells in various lymphomas and leukemias, as well as normal B cells. Upon infusion into a patient, these modified T cells target and eliminate CD19-positive cells, leading to B cell aplasia. This mechanism is leveraged for the treatment of relapsed or refractory B-cell malignancies and is also being explored for autoimmune diseases where B cells play a pathogenic role.

Other names

Anti-CD19-CAR-T cellsAnti-CD-19-CAR-T cellsAnti-CD 19-CAR-T cellsCD19 chimeric antigen receptor (CAR)-Modified T CellsCD19-targeted T cellsCD-19-targeted T cellsCD 19-targeted T cellsCD19-directed CAR-modified T cellsCD-19-directed CAR-modified T cellsCD 19-directed CAR-modified T cellssecond-generation CAR-T cellsnon-viral genome targeting anti-CD19 chimeric antigen receptor T cellsautologous anti-CD19 (human derived) chimeric antigen receptor T cellsautologous anti-CD19 (mice derived) chimeric antigen receptor T cellsdonor-derived anti-CD19 CAR-T cells